<DOC>
	<DOCNO>NCT02524379</DOCNO>
	<brief_summary>The purpose study determine safety use oral Glyburide ( DiaBeta ) patient acute traumatic cervical spinal cord injury ( SCI ) .</brief_summary>
	<brief_title>Spinal Cord Injury Neuroprotection With Glyburide</brief_title>
	<detailed_description>This study include patient 18 80 year experience acute traumatic cervical spinal cord injury ( specifically ASIA A , B C ) . Patients begin oral drug regimen Glyburide ( DiaBeta ) , must start within 8 hour injury continue 72 hour daily dose 3.125 mg Day 1 , 2.5 mg Day 2 2.5 mg Day 3 . If indicate , patient also surgical intervention spinal cord decompression spinal stabilization . Every one take part study labs draw adverse event assess Day 14 discharge ( whichever earlier ) , carefully monitor throughout hospitalization . Study participation last 365 day ( +/- 30 day ) , post-hospitalization follow occuring Days 28 , 42 , 84 , 182 365 .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>1 . Age : ≥ 18 year ≤ 80 year 2 . Written informed consent patient legal authorize representative 3 . No lifethreatening injury 4 . No evidence sepsis 5 . Acute cervical SCI ASIA Impairment Scale grade A , B C admission 6 . Nonpenetrating SCI neurologic level C2 C8 7 . Initiation study drug within 8 hour injury Exclusion Criteria 1 . Unconsciousness mental impairment prevents neurological assessment within first 8 hour 2 . Acute SCI ASIA Impairment Scale grade D E 3 . Currently involve another nonobservational SCI research study receive another investigational drug 4 . History hypersensitivity sulfonylurea , particular glyburide , component 5 . Other illness ( include mental disorder ) could preclude accurate medical neurological evaluation ( discretion site investigator ) 6 . Unable commit followup schedule 7 . A recent history regular substance abuse ( illicit drug , alcohol ) , opinion investigator would interfere subject 's participation study 8 . Any condition likely result patient 's death within next 12 month 9 . Prisoner 10 . Severe renal disorder patient 's history ( e.g . dialysis ) baseline eGFR &lt; 30 mL/min/1.73 m2 11 . Known severe liver disease , ALT &gt; 3 time upper limit normal bilirubin &gt; 2 time upper limit normal . Subjects may randomize liver function test draw yet available subject know history liver disease ; however , treatment DiaBeta discontinue prior second dose liver function test indicate ALT &gt; 3 time upper limit normal bilirubin &gt; 2 time upper limit normal 12 . Blood glucose &lt; 55 mg/dL enrollment immediately prior administration DiaBeta , clinically significant history hypoglycemia 13 . Acute ST elevation myocardial infarction , and/or acute decompensated heart failure , and/or QTc &gt; 520 m , and/or know history cardiac arrest ( PEA , VT , VF , asystole ) , and/or admission acute coronary syndrome , myocardial infarction , coronary intervention ( percutaneous coronary intervention coronary artery surgery ) within past 3 month 14 . Known treatment Bosentan within past 7 day 15 . Known G6PD enzyme deficiency 16 . Pregnancy : Women must either postmenopausal , permanently sterilize , ≤ 50 year old , must negative test pregnancy obtain enrollment 17 . Breastfeeding woman agree stop breastfeed 7 day follow end oral glyburide administration 18 . Subjects opinion investigator suitable inclusion study ( reason document ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>